Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday, marking the end of the Bluebird's fall from the one of the buzziest biotech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback